Please ensure Javascript is enabled for purposes of website accessibility

Royalty Pharma Pulls the Off Largest IPO of 2020

By Cory Renauer – Jun 16, 2020 at 5:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The initial public offering was for a pharmaceutical company that doesn't want to make or sell any drugs.

Investors' pandemic-driven appetites for shares of newly listed biopharmaceutical companies seem to know no bounds in 2020. Royalty Pharma (NASDAQ: RPRX) made its stock market debut at $44 per share on Tuesday, valuing the company at a whopping $26.2 billion and the market pushed the stock more than 60% higher during its first day of trading. 

The size of the offering was raised from 70,000,000 million shares to 77,680,670 shares, and the company will most likely sell an additional 11,652,250 to the offering's underwriters. 

A great big pile of cash money

Image source: Getty Images.

Thinking long term 

The largest initial public offering of 2020 so far is a pharma company that has no intention of developing or sell any drugs directly. As the name implies, Royalty Pharma helps other biopharmaceutical companies by giving them cash to use for drug development in exchange for a percentage of any future sales those drugs might generate. 

They can't all be winners, but the company only needs to pick well a handful of times and hang on tight to eventually produce steady profits for its shareholders. For example, in 2014 the Cystic Fibrosis Foundation sold Royalty Pharma a share of the royalties for cystic fibrosis treatments developed by Vertex Pharmaceuticals (VRTX -1.11%) for $3.3 billion.

First-quarter sales of Vertex's cystic fibrosis drugs soared 77% year over year to an annualized $6.1 billion. Royalty Pharma is entitled to a percentage of these drugs' sales that ranges from the low- to mid-single digits. The company (and its investors) expect those royalties will flow steadily through 2037.

Royalty Pharma's most recent investment entitles the company to a percentage of the Idhifa sales that Bristol Myers Squibb (BMY -0.86%) owes its collaboration partner, Agios Pharmaceuticals (AGIO -1.01%).

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$289.54 (-1.11%) $-3.26
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$71.09 (-0.86%) $0.62
Agios Pharmaceuticals, Inc. Stock Quote
Agios Pharmaceuticals, Inc.
AGIO
$28.28 (-1.01%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.